No abstract

P atients (>90% type 1 diabetes) using real timecontinuous glucose monitoring (RT-CGM) for more than 3 months were asked to complete a questionnaire on type and duration of diabetes, self-reported complications, subjective reasons for RT-CGM use, source of payment for RT-CGM, personal income, time on the sensor, but also information such as perceived burden of diabetes, admissions for severe hypoglycaemia or ketoacidosis before and since commencing RT-CGM use. Of the 150 patients supplied with the questionnaire it was completed by 89%. Compliance was high with 77% reporting RT-CGM use ≥75% of the time. The proportion of patients having an HbA 1c of ≤7% increased from 33% to 73% (p<0.001). Severe hypoglycaemia and hospital admissions for hypoglycaemia and ketoacidosis also decreased significantly. Patient satisfaction with the device was high. The impact of living with diabetes in daily life improved from 4.1 to 3.4 (p<0.001). The hypoglycaemia alarm was most appreciated.In summary, we confirm that RT-CGM can be a valuable tool to support patients in the self-management of their type 1 diabetes in real life practice if they are willing and able to use the device at least 75% of the time. Br J Diabetes Vasc Dis 2011;11:145-149.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

The result of the analysis confirms an increase in appropriateness of 7.51%.In the two periods compared, there was an increase in reports that also produced an economic saving of C ¼ 33,619.12. Conclusion The analysis shows that the role of the pharmacist is fundamental, both to ensure the effectiveness and efficiency of the therapies and to limit the costs of pharmaceuticals and health in general.